May 26, 2017 9:56 PM ET


Company Overview of Carmot Therapeutics, Inc.

Company Overview

Carmot Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of metabolic diseases, cancer, and inflammation. It develops Chemotype Evolution, a technology that enables the rapid identification of drugs through a lead-identification paradigm for the discovery of therapeutics. The company’s therapeutic portfolio pipeline includes GLP-1R and dual GLP-1R/GIPR agonists, which are peptide-small molecule hybrid compounds that activate GLP-1R and GIPR; NEMO/IKK to block pathological NF-kB signaling for therapeutic applications in inflammatory, auto-immune, and oncology diseases; deubiquitinating enzymes that remove ubiquitin from proteins targeted for degradati...

409 Illinois Street

San Francisco, CA 94158

United States

Founded in 2008





Key Executives for Carmot Therapeutics, Inc.

Co-Founder, Chief Executive Officer and Director
President and Director
Director of Business Development & Operations
Vice President of Business Development
Vice President of Clinical Development
Compensation as of Fiscal Year 2016.

Carmot Therapeutics, Inc. Key Developments

Carmot Therapeutics, Inc. Announces Board Changes

Carmot Therapeutics, Inc. announced that Dr. Trombley joins company's Board of Directors as an independent director. She is Vice President, Chief Operating Officer of NGM Biopharmaceuticals. She joined NGM as head of Business Development in 2011. She was most recently from Novartis in Basel, Switzerland, where she was Chief of Staff for the Chief Executive Officer and worked on key corporate initiatives and strategic projects across the company’s healthcare businesses. Previously, she was Associate Director, Business Development at XenoPort, Inc. Elena Viboch, Director of Business Development and Operations, joins Carmot from FLX Bio, where she served as Senior Manager of Corporate Development and Strategy. Prior to FLX Bio, Elena Viboch worked in New Product Planning with Jazz Pharmaceuticals.

Carmot Therapeutics Enters into Collaboration and License Agreement with Genentech, Inc

Carmot Therapeutics, Inc. has entered into a drug discovery collaboration and license agreement with Genentech, Inc. As part the agreement, Carmot will apply its lead-identification technology, Chemotype Evolution, to discover novel drug hits. Carmot and Genentech will work together to identify lead candidates, while Genentech will be solely responsible for lead optimization, pre-clinical and clinical development, manufacturing, and commercialization activities. Under the terms of the agreement, Carmot will receive an undisclosed upfront payment and is eligible to receive milestone payments based on achievement of certain predetermined pre-clinical and clinical milestones. In addition, Carmot is eligible to receive royalties on sales of certain products resulting from the license agreement. Financial terms have not been disclosed.

Amgen and Carmot Therapeutics Extend R&D Collaboration

Carmot Therapeutics Inc. announced an extension to the R&D partnership struck in 2014 with Amgen Inc. Carmot will continue to utilise its proprietary lead-identification technology, Chemotype Evolution, to advance further molecules discovered as part of the initial collaboration. The clinical development of any newly discovered molecules will be the sole responsibility of Amgen. The agreement gives Carmot the right to research funding, as well as payments tied to pre-clinical and clinical milestones. The company will also be eligible for royalties on commercial sales of products resulting from this collaboration. The financial terms agreed by the parties were not disclosed.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Carmot Therapeutics, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at